These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3674250)

  • 1. Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene.
    Soumerai SB; Avorn J; Gortmaker S; Hawley S
    Am J Public Health; 1987 Dec; 77(12):1518-23. PubMed ID: 3674250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deaths related to propoxyphene overdose: a ten-year assessment.
    Wetli CV; Bednarczyk LR
    South Med J; 1980 Sep; 73(9):1205-9. PubMed ID: 7414379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining product risk in context. Market withdrawal of zomepirac as a case study.
    Ross-Degnan D; Soumerai SB; Fortess EE; Gurwitz JH
    JAMA; 1993 Oct; 270(16):1937-42. PubMed ID: 8411550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-poisoning with dextropropoxyphene and dextropropoxyphene compounds: the USA experience.
    Finkle BS
    Hum Toxicol; 1984 Aug; 3 Suppl():115S-134S. PubMed ID: 6480011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidepressant Regulatory Warnings, Prescription Patterns, Suicidality and Other Aggressive Behaviors in Major Depressive Disorder and Anxiety Disorders.
    Gupta S; Gersing KR; Erkanli A; Burt T
    Psychiatr Q; 2016 Jun; 87(2):329-42. PubMed ID: 26303613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In brief: propoxyphene toxicity.
    Med Lett Drugs Ther; 2010 Sep; 52(1346):69. PubMed ID: 20814401
    [No Abstract]   [Full Text] [Related]  

  • 8. Fatal poisonings involving propoxyphene before and after voluntary withdrawal from the United States' market: An analysis from the state of Florida.
    Delcher C; Chen G; Wang Y; Slavova S; Goldberger BA
    Forensic Sci Int; 2017 Nov; 280():228-232. PubMed ID: 29080523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of state rules on opioid prescribing in Indiana.
    Al Achkar M; Grannis S; Revere D; MacKie P; Howard M; Gupta S
    BMC Health Serv Res; 2018 Jan; 18(1):29. PubMed ID: 29347984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A national assessment of propoxyphene in postmortem medicolegal investigation, 1972-1975.
    Finkle BS; McCloskey KL; Kiplinger GF; Bennett IF
    J Forensic Sci; 1976 Oct; 21(4):706-41. PubMed ID: 972299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.
    Larochelle MR; Zhang F; Ross-Degnan D; Wharam JF
    JAMA Intern Med; 2015 Jun; 175(6):978-87. PubMed ID: 25895077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA Boxed Warning for Immediate-Release Opioids.
    Food And Drug Administration Public Health Service U S Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2016 Jun; 30(2):141-5. PubMed ID: 27301692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propoxyphene (dextropropoxyphene): a critical review of a weak opioid analgesic that should remain in antiquity.
    Barkin RL; Barkin SJ; Barkin DS
    Am J Ther; 2006; 13(6):534-42. PubMed ID: 17122535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-risk use by patients prescribed opioids for pain and its role in overdose deaths.
    Gwira Baumblatt JA; Wiedeman C; Dunn JR; Schaffner W; Paulozzi LJ; Jones TF
    JAMA Intern Med; 2014 May; 174(5):796-801. PubMed ID: 24589873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Florida's Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use.
    Rutkow L; Chang HY; Daubresse M; Webster DW; Stuart EA; Alexander GC
    JAMA Intern Med; 2015 Oct; 175(10):1642-9. PubMed ID: 26280092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indices of drug misuse for prescription drugs.
    Davis H; Baum C; Graham DJ
    Int J Addict; 1991 Jul; 26(7):777-95. PubMed ID: 1960000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in Florida's Prescription Drug Monitoring Program registration and utilization: Implications for increasing voluntary use.
    Delcher C; Wang Y; Young HW; Goldberger BA; Schmidt S; Reisfield GM
    J Opioid Manag; 2017; 13(5):283-289. PubMed ID: 29199394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vital Signs: Changes in Opioid Prescribing in the United States, 2006-2015.
    Guy GP; Zhang K; Bohm MK; Losby J; Lewis B; Young R; Murphy LB; Dowell D
    MMWR Morb Mortal Wkly Rep; 2017 Jul; 66(26):697-704. PubMed ID: 28683056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Propoxyphene dependence: an update.
    Collins GB; Kiefer KS
    Postgrad Med; 1981 Dec; 70(6):57-61. PubMed ID: 7312731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the black triangle label on prescribing of new drugs in the United Kingdom: lessons for the United States at a time of deregulation.
    Horton DB; Gerhard T; Davidow A; Strom BL
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1307-1313. PubMed ID: 28857309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.